Karam JA - Search Results

1

Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.

Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Shariat SF, et al. Among authors: karam ja. Eur Urol. 2005 Sep;48(3):424-31. doi: 10.1016/j.eururo.2005.04.034. Eur Urol. 2005. PMID: 15963628

2

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.

Shulman MJ, Karam JA, Benaim EA. Shulman MJ, et al. Among authors: karam ja. Urology. 2004 Apr;63(4):732-6. doi: 10.1016/j.urology.2003.11.016. Urology. 2004. PMID: 15072890

3

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.

Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Svatek R, et al. Eur Urol. 2006 Apr;49(4):666-74. doi: 10.1016/j.eururo.2005.11.032. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16423446

4

The application of epigenetic modifiers on the treatment of prostate and bladder cancer.

Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. Zhang Z, et al. Urol Oncol. 2006 Mar-Apr;24(2):152-60. doi: 10.1016/j.urolonc.2005.11.004. Urol Oncol. 2006. PMID: 16520279 Review.

5

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Karam JA, et al. Lancet Oncol. 2007 Feb;8(2):128-36. doi: 10.1016/S1470-2045(07)70002-5. Lancet Oncol. 2007. PMID: 17267327

6

Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.

Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Karam JA, et al. Prostate. 2007 May 1;67(6):614-22. doi: 10.1002/pros.20557. Prostate. 2007. PMID: 17299799

7

Blood biomarkers for prostate cancer detection and prognosis.

Shariat SF, Karam JA, Roehrborn CG. Shariat SF, et al. Among authors: karam ja. Future Oncol. 2007 Aug;3(4):449-61. doi: 10.2217/14796694.3.4.449. Future Oncol. 2007. PMID: 17661720 Review.

8

Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.

Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Karam JA, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4400-6. doi: 10.1158/1078-0432.CCR-07-0287. Clin Cancer Res. 2007. PMID: 17671122

9

Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.

Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Shariat SF, et al. Among authors: karam ja. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5377-84. doi: 10.1158/1078-0432.CCR-07-0330. Clin Cancer Res. 2007. PMID: 17875766

10

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Karam JA, et al. Urology. 2007 Sep;70(3):482-6. doi: 10.1016/j.urology.2007.05.009. Urology. 2007. PMID: 17905101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

295 results

Search Page

Filters